Concepts and surgical treatment of metastatic bone disease

Kristy Weber, Scott Kominsky

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter focuses on treatment that affects the neoplastic process as well as the bone microenvironment. It discusses the molecular events related to metastatic bone disease and summarizes the use of bisphosphonate or anti-RANKL therapy as well as surgical stabilization in these settings. Colonization and growth of tumor cells in the bone can be thought of as occurring in three phases: colonization, dormancy, and expansion. Radium-223 dichloride is a radiopharmaceutical approved for use in the treatment of prostate cancer bone metastasis. As patients with bone metastasis are unlikely to be surgically cured, the primary focus of orthopedic oncologists is to improve quality of life. The goals of surgical treatment of patients with bone metastasis are to improve function and decrease pain. In selected patients, minimally invasive procedures provide an alternative to surgery and can produce long-lasting pain relief.

Original languageEnglish (US)
Title of host publicationPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
Publisherwiley
Pages816-821
Number of pages6
ISBN (Electronic)9781119266594
ISBN (Print)9781119266563
DOIs
StatePublished - Jan 1 2018

    Fingerprint

Keywords

  • Anti-RANKL therapy
  • Bisphosphonate
  • Bone metastasis
  • Metastatic bone disease
  • Minimally invasive procedures
  • Neoplastic process
  • Orthopedic oncologists
  • Surgical treatment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Weber, K., & Kominsky, S. (2018). Concepts and surgical treatment of metastatic bone disease. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (pp. 816-821). wiley. https://doi.org/10.1002/9781119266594.ch106